{
    "symbol": "BTAI",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-09 12:18:13",
    "content": " The first part is similar to our SERENITY I and II trials, which were the basis for our IGALMI approval earlier this year, and is designed to assess efficacy and safety in acutely agitated bipolar and schizophrenia patients in an institutional setting. Moving on to the third and final pillar for our 501 expansion strategy, growing geographic footprint, given the significant near-term U.S. market opportunities, the company has available by developing 501 for bipolar I and II and in schizophrenia patients in the home setting and as an adjunctive treatment for MDD, we have made the strategy choice to prioritize resources to execute on U.S. strategy over ex-U.S. As a result, we have chosen not to file an MAA at this time, we fully intend to pursue a well timed geographic expansion at the most appropriate and opportune time. Please proceed with your question. Please proceed with your question. Please proceed with your question. Please proceed with your question. Please proceed with your question. So there were no safety concerns, or any reasons that we could not do the first portion in at-home setting, as I mentioned previously, it's all about having the robustness of the data and using the scale that we have used in SERENITY I and II, and we were able to use this and at the same time demonstrate the safety at-home, so that it can become a package to for label expansion or for another SNDA. Please proceed with your question. Please proceed with your question. Please proceed with your question."
}